Regulus Therapeutics Inc (RGLS) stock saw a modest uptick, ending the day at $1.82 which represents a slight increase of $0.11 or 6.43% from the prior close of $1.71. The stock opened at $1.7 and ...

Fintel reports that on September 13, 2024, Oppenheimer downgraded their outlook for Moderna (NasdaqGS:MRNA) from Outperform ...

To determine American audiences’ 50 favorite actors who are men, Stacker analyzed data from YouGov, current as of June 2024.

Fintel reports that on September 3, 2024, Oppenheimer initiated coverage of Fair Isaac (NYSE:FICO) with a Outperform ...

The current year, in contrast, has seen audiences remain far more discerning in terms of their film choices, staying away ...

Seres Therapeutics Inc (MCRB) stock saw a modest uptick, ending the day at $1.03 which represents a slight increase of $0.08 or 8.42% from the prior close of $0.95. The stock opened at $0.96 and ...

Oppenheimer analyst Colin Rusch maintained a Hold rating on ChargePoint Holdings (CHPT – Research Report) today. The company’s ...

In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $115.00. The company’s shares closed last Friday at ...

Significant Grifols shareholders fill a vacant board seat, appointing pharma leader Paul Herendeen to drive value and improve ...

Oppenheimer维持对Addus HomeCare (NASDAQ:ADUS)的"跑赢大盘"评级，同时将公司目标股价从140美元上调至145美元。在最近与Addus HomeCare管理层会面后，该公司对其年底前的前景表示乐观。 这家家庭护理服务提供商显示出运营趋势改善的迹象，员工流动率和生产力均从疫情期间的低谷中恢复。这一改善正值公司期待在2024年第四季度完成对Gentiva的收购。预计 ...

The National Association of Theatre Owners announced a multibillion-dollar renovation plan that encompasses 21,000 screens — ...

The strong year-to-date gains have introduced caution among market participants, especially because the uncertainties are yet ...